Mineralys Therapeutics, Inc. (MLYS) Tops Q4 EPS by 54c

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) reported Q4 EPS of ($0.40), $0.54 better than the analyst estimate of ($0.94). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on Mineralys Therapeutics, Inc. (MLYS) click here.

You May Also Be Interested In

• Godaddy Gets Takeover Offer From Gen Digital - FT
• SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance
• Vishay launches four thick film resistor sample kits for high power designs